Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
BLX 0.57ELF.TO 0.09RY.TO 3.05PEY.TO 0.26CP.TO -0.12BRK.B -0.57MSFT -5.93META 6.73
Angiotech Pharmaceuticals (ANP.TO)

Angiotech Pharmaceuticals (ANP.TO)

0.00
-0.00 (0.00%)
2 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
WATCH

Angiotech Pharmaceuticals(ANP.TO)

Sep 15, 2003
Had a price gap in June. There was a testing of that level recently. If it broke through that level, it would be bad news.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTAUnlock Rating
$68.05

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Aug 26, 2003
Will continue to be a winner in the marketplace.At some point it will be acquired.Has had an enormous move, so be cautious and wait for a correction.
Photo of Brendan KyneBrendan KyneUnlock Rating
$60.97

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

Jul 14, 2003
Slightly overvalued, but has potential.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$60.05

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Jun 13, 2003
Prefers Boston Scientific.
Photo of Ian AinsworthIan Ainsworth
No
Unlock Rating
$54.60

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Apr 04, 2003
Concerned about their ability to raise cash.
Photo of Bill MacLachlanBill MacLachlanUnlock Rating
$31.91

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

Feb 07, 2003
Very news sensitive. From here, its a reasonable stock to own.
Photo of Robert FloydRobert FloydUnlock Rating
$54.70

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

Jan 22, 2003
There is a big market for theior products. Speculative.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$54.55

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Jan 14, 2003
A long way from being a mature company with mature products. Speculative.
Photo of David BaskinDavid BaskinUnlock Rating
$51.26

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Angiotech Pharmaceuticals(ANP.TO)

Nov 04, 2002
(Was a top pick on Aug 7. Down 16.7%.) Still likes.
Photo of John EmbryJohn EmbryUnlock Rating
$57.51

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Angiotech Pharmaceuticals(ANP.TO)

Aug 07, 2002
Will be in commercial product in Europe and US in the next year or two. Soundly financed.
Photo of John EmbryJohn EmbryUnlock Rating
$68.89

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Angiotech Pharmaceuticals(ANP.TO)

Jul 19, 2002
(Was a top pick on Apr 1. Down 25%) Will probably be purchasing more, but at a later date.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$53.78

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

May 01, 2002
Nice technology. In early stage. Should go up.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$60.50

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

Apr 24, 2002
Trials have gone well. Risk/Reward is good.
Photo of John ZechnerJohn ZechnerUnlock Rating
$67.43

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Angiotech Pharmaceuticals(ANP.TO)

Apr 11, 2002
(Was a top pick on March 5 up 7%) Still likes.
Photo of John ZechnerJohn ZechnerUnlock Rating
$71.51

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Angiotech Pharmaceuticals(ANP.TO)

Apr 01, 2002
Higher risk. Good price.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$72.45

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 106 to 120 of 140 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AVGO -17.23$376.71
CCO.TO 1.26$151.04
TOU.TO -0.47$60.79
BTE.TO -0.22$5.91
ADM -1.25$78.02
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

BLX 0.57$59.24
ELF.TO 0.09$16.98
RY.TO 3.05$281.51
PEY.TO 0.26$24.91
CP.TO -0.12$124.8

Popular Articles

Latest Sell Signals

OTEX.TO 0.14$30.96
BSX 0.16$46.92
GIL.TO -16.24$70.39
SHOP.TO 1.22$158.49
WCN.TO 3.21$219.59

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video